Targeting PD-L1/CMTM6 in myeloid cells results in elevated release of CCL2 to improve CD8 T cell-mediated antitumor response

被引：0
|
作者：
Hsu, Michelle Alexandria
Liu, Xin
Li, Ying
Barham, Whitney
Pavelko, Kevin
Hirdler, Jake
Lucien, Fabrice
Dong, Haidong
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-2664
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2664
引用
收藏
页数：2
相关论文
共 50 条
  • [31] QSOX1 facilitates dormant esophageal cancer stem cells to evade immune elimination via PD-L1 upregulation and CD8 T cell exclusion
    Wei, Jia-Ru
    Zhang, Baifeng
    Zhang, Yu
    Chen, Wo-Ming
    Zhang, Xiao-Ping
    Zeng, Ting-Ting
    Li, Yan
    Zhu, Ying-Hui
    Guan, Xin-Yuan
    Li, Lei
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2024, 121 (44)
  • [32] Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer (vol 6, pg 1426, 2018)
    O'Malley, G.
    Treacy, O.
    Lynch, K.
    Naicker, S. D.
    Leonard, N. A.
    Lohan, P.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (01) : 162 - 162
  • [33] Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer
    Zhou, Xumin
    Zou, Libin
    Liao, Hangyu
    Luo, Junqi
    Yang, Taowei
    Wu, Jun
    Chen, Wenbin
    Wu, Kaihui
    Cen, Shengren
    Lv, Daojun
    Shu, Fangpeng
    Yang, Yu
    Li, Chun
    Li, Bingkun
    Mao, Xiangming
    ACTA PHARMACEUTICA SINICA B, 2022, 12 (02) : 692 - 707
  • [34] Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
    Nojima, Yuji
    Shimizu, Katsuhiko
    Saisho, Shinsuke
    Maeda, Ai
    Kurosaki, Takeshi
    Kurose, Koji
    Oga, Toru
    Oka, Mikio
    Nakata, Masao
    ANTICANCER RESEARCH, 2021, 41 (11) : 5469 - 5475
  • [35] PD-L1 Expression and CD8 Positive T Cell Tumor Infiltrate Level Predict Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Rosainz, Manuel Arana
    Gayhart, Matthew
    Chaum, Manita
    Eno, Celeste
    Song, Jianbo
    Medeiros, Fabiola
    Vail, Eric
    Lopategui, Jean
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1089 - 1090
  • [36] PD-L1 Expression and CD8 Positive T Cell Tumor Infiltrate Level Predict Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Rosainz, Manuel Arana
    Gayhart, Matthew
    Chaum, Manita
    Eno, Celeste
    Song, Jianbo
    Medeiros, Fabiola
    Vail, Eric
    Lopategui, Jean
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 1089 - 1090
  • [37] Deficiency in B7-H1 (PD-L1)/PD-1 Coinhibition Triggers Pancreatic β-Cell Destruction by Insulin-Specific, Murine CD8 T-Cells
    Rajasalu, Tarvo
    Brosi, Helen
    Schuster, Cornelia
    Spyrantis, Andreas
    Boehm, Bernhard Otto
    Chen, Lieping
    Reimann, Joerg
    Schirmbeck, Reinhold
    DIABETES, 2010, 59 (08) : 1966 - 1973
  • [38] Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eμ-TCL1 CLL mouse model
    McClanahan, Fabienne
    Riches, John C.
    Miller, Shaun
    Day, William P.
    Kotsiou, Eleni
    Neuberg, Donna
    Croce, Carlo M.
    Capasso, Melania
    Gribben, John G.
    BLOOD, 2015, 126 (02) : 212 - 221
  • [39] Interference with PD-L1/PD-1 co-stimulation results in effective anti-tumour immunity by preventing ligand-induced T cell receptor down-modulation in effector CD8 T cells
    Escors, D.
    Liechtenstein, T.
    Perez-Janices, N.
    Lanna, A.
    Bricogne, C.
    Karwaca, K.
    Guerrero-Setas, D.
    Breckpot, K.
    HUMAN GENE THERAPY, 2013, 24 (12) : A170 - A170
  • [40] The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors
    Romano, Emanuela
    Romero, Pedro
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
12345